从非酒精性脂肪性肝病（NAFLD）转变为代谢功能障碍相关脂肪性肝病（MASLD）时，无需进行确证性生物标志物诊断研究。 - Suppr

Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.

作者信息

Ratziu Vlad, Boursier Jérôme

机构信息

Sorbonne Université, Institute of Cardiometabolism and Nutrition, Hospital Pitié Salpêtrière, Paris, France.

Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, HIFIH Laboratory, SFR ICAT 4208, Angers University, Angers, France.

出版信息

J Hepatol. 2024 Feb;80(2):e51-e52. doi: 10.1016/j.jhep.2023.07.017. Epub 2023 Aug 3.

DOI:10.1016/j.jhep.2023.07.017

PMID:37543307

Abstract

摘要

相似文献

Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.从非酒精性脂肪性肝病（NAFLD）转变为代谢功能障碍相关脂肪性肝病（MASLD）时，无需进行确证性生物标志物诊断研究。

J Hepatol. 2024 Feb;80(2):e51-e52. doi: 10.1016/j.jhep.2023.07.017. Epub 2023 Aug 3.

Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.代谢相关脂肪性肝病和非酒精性脂肪性肝病的临床特征和病死率相似。

J Hepatol. 2024 May;80(5):694-701. doi: 10.1016/j.jhep.2024.01.014. Epub 2024 Jan 27.

[Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].基于临床特征分析非酒精性脂肪性肝病与代谢功能障碍相关脂肪性肝病的差异

Zhonghua Gan Zang Bing Za Zhi. 2024 Apr 20;32(4):346-353. doi: 10.3760/cma.j.cn501113-20231022-00153.

Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.甘油三酯-葡萄糖相关指标与非酒精性脂肪性肝病或代谢相关脂肪性肝病患者死亡的相关性。

Cardiovasc Diabetol. 2024 Jul 4;23(1):232. doi: 10.1186/s12933-024-02343-7.

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD.从非酒精性脂肪性肝病转变为代谢功能障碍相关脂肪性肝病：非酒精性脂肪性肝病和代谢功能障碍相关脂肪性肝病之间反流性食管炎的累积发病率相似。

Clin Mol Hepatol. 2024 Jan;30(1):121-123. doi: 10.3350/cmh.2023.0437. Epub 2023 Dec 4.

Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.经活检证实的代谢相关脂肪性肝病的预后：CLIONE 研究的亚分析。

Clin Mol Hepatol. 2024 Apr;30(2):225-234. doi: 10.3350/cmh.2023.0515. Epub 2024 Jan 24.

Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.代谢相关脂肪性肝病与冠状动脉 CT 血管造影结果的预后价值比较：与非酒精性脂肪肝的比较。

Cardiovasc Diabetol. 2024 May 10;23(1):167. doi: 10.1186/s12933-024-02268-1.

From NAFLD to MASLD: When metabolic comorbidity matters.从非酒精性脂肪性肝病到代谢相关性脂肪性肝病：当代谢合并症起重要作用时。

Ann Hepatol. 2024 Mar-Apr;29(2):101281. doi: 10.1016/j.aohep.2023.101281. Epub 2023 Dec 21.

Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.脂肪性肝病新命名法的意义及代谢相关脂肪性肝病的定义。

Aliment Pharmacol Ther. 2024 Jan;59(2):150-156. doi: 10.1111/apt.17846.

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD.从非酒精性脂肪性肝病转变为代谢相关脂肪性肝病：在阿替利珠单抗/贝伐单抗治疗下，非酒精性脂肪性肝病和代谢相关脂肪性肝病患者发生肝细胞癌的预后相似。

Clin Mol Hepatol. 2024 Apr;30(2):263-265. doi: 10.3350/cmh.2023.0557. Epub 2024 Jan 18.

引用本文的文献

Metabolic Dysfunction-Associated Steatotic Liver Disease Is Characterized by Enhanced Endogenous Cholesterol Synthesis and Impaired Synthesis/Absorption Balance.代谢功能障碍相关脂肪性肝病的特征是内源性胆固醇合成增强以及合成/吸收平衡受损。

Int J Mol Sci. 2025 Aug 1;26(15):7462. doi: 10.3390/ijms26157462.

Beyond BMI: revealing metabolic risk in lean MASLD.超越体重指数：揭示瘦型代谢相关脂肪性肝病的代谢风险。

Arch Clin Cases. 2025 Aug 4;12(3):110-118. doi: 10.22551/2025.48.1203.10322. eCollection 2025.

Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.甘油三酯-血糖-腰围指数：代谢功能障碍相关脂肪性肝病的有力工具。

World J Hepatol. 2025 Jul 27;17(7):107668. doi: 10.4254/wjh.v17.i7.107668.

Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.与临床结局相关的代谢相关脂肪性肝病新亚型：对精准医学的启示

J Transl Med. 2025 Jul 10;23(1):769. doi: 10.1186/s12967-025-06670-5.

Adoption of the New Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by the Indian National Association for Study of the Liver (INASL): Implications for the INASL Guidance Paper on NAFLD.印度国家肝脏研究协会（INASL）采用代谢功能障碍相关脂肪性肝病（MASLD）新命名法：对INASL非酒精性脂肪性肝病指南文件的影响

J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102590. doi: 10.1016/j.jceh.2025.102590. Epub 2025 May 16.

Metabolic associated steatotic liver disease in renal transplant recipients: a retrospective cohort study.肾移植受者的代谢相关脂肪性肝病：一项回顾性队列研究

Intern Emerg Med. 2025 May 31. doi: 10.1007/s11739-025-03967-7.

Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation.弥合肥胖研究差距：欧洲临床研究学会的共识声明

Eur J Clin Invest. 2025 Aug;55(8):e70059. doi: 10.1111/eci.70059. Epub 2025 May 15.

Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD.代谢综合征与肝脏疾病：从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病范式转变下的筛查、诊断及治疗再评估

J Clin Med. 2025 Apr 16;14(8):2750. doi: 10.3390/jcm14082750.

Characteristics of Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Risk for Hepatic Fibrosis in 476,124 Korean Adults: A Cross-Sectional Study.476,124名韩国成年人中代谢功能障碍相关脂肪性肝病的特征及其肝纤维化风险：一项横断面研究

Endocrinol Metab (Seoul). 2025 Mar 27. doi: 10.3803/EnM.2024.2281.

Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma.代谢功能障碍相关脂肪性肝病（MASLD）相关肝细胞癌的致病机制

Cells. 2025 Mar 13;14(6):428. doi: 10.3390/cells14060428.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献